Ignite Creation Date:
2024-05-06 @ 10:51 AM
Last Modification Date:
2024-10-26 @ 12:36 PM
Study NCT ID:
NCT03367715
Status:
COMPLETED
Last Update Posted:
2022-07-01
First Post:
2017-12-05
Brief Title:
Nivolumab Ipilimumab and Short-course Radiotherapy in Adults With Newly Diagnosed MGMT Unmethylated Glioblastoma
Sponsor:
NYU Langone Health
Organization:
NYU Langone Health
Study Overview
Official Title:
A Phase II Open-label Single Arm Trial of Nivolumab Ipilimumab and Short-course Radiotherapy in Adults With Newly Diagnosed MGMT Unmethylated Glioblastoma
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single arm open-label phase II trial of nivolumab ipilimumab and short-course radiation therapy in adult patients with newly diagnosed MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None